-
-
-
-
-
-
-
B.Riley Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
-
-
-
-
-
-
Capricor reports positive HOPE-3 trial results for Duchenne therapy
-
-
-
-
-
-
-
CAPR receives FDA request for clinical study report on Deramiocel
-
-
-
-
-
-
-
B.Riley Starts Capricor Therapeutics (CAPR) at Buy
-
-
-
-
-
-
-
Capricor Therapeutics Announces Orphan Drug Designation for Becker Muscular Dystrophy and Regulatory Progress for Duchenne Muscular Dystrophy Program
-
-
-
-
-
-
-
Capricor Therapeutics (CAPR) Announces Completion of Mid-Cycle Review Meeting with FDA on Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Capricor Therapeutics (CAPR)
-
15,579 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

